AR062994A1 - Derivados de quinolina con actividad sobre el receptor 5-ht5a - Google Patents

Derivados de quinolina con actividad sobre el receptor 5-ht5a

Info

Publication number
AR062994A1
AR062994A1 ARP070104247A ARP070104247A AR062994A1 AR 062994 A1 AR062994 A1 AR 062994A1 AR P070104247 A ARP070104247 A AR P070104247A AR P070104247 A ARP070104247 A AR P070104247A AR 062994 A1 AR062994 A1 AR 062994A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
ch2o
links
ht5a
receiver
Prior art date
Application number
ARP070104247A
Other languages
English (en)
Inventor
Sabine Kolczewski
Thomas Woltering
Claus Riemer
Juergen Wichmann
Lucinda Steward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR062994A1 publication Critical patent/AR062994A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Compuestos de la formula (1) o sales farmacéuticamente aceptables de los mismos, en la que X es un enlace, -CH2CH2-, -CH=CH-, -CH2O-, -CH2NR-, -CH2S(O)-, -CH2S(O)2-, -O-, -OCH2CH2-, -S-, -SCH2-, -OCH2CH2S(O)-, -OCH2CH2S(O)2-, -CH2NRCO-, -CH2NRCH2-, grupo de formulas (2), -NRS(O)2NR-, -NHCHR-, -NR- o -NRS(o)2-; y en la que X puede insertarse en ambas direcciones dentro de la formula (1); Y es un enlace, -CHR- o -OCH2CH2-; R es hidrogeno o alquilo inferior; Ar1/Ar2 con independiencia entre sí son arilo o heteroarilo de 5 a 10 eslabones, opcionalmente sustituido por alquilo inferior, alcoxi inferior, haloalcoxi inferior, halogeno, -CF3, -CH2OH, -CH2O-alquilo inferior, cicloalquilo de 3 a 10 eslabones, heterocicloalquilo de 5 a 10 eslabones, -CH2O(CH2)2O-alquilo inferior, -S(O)2-alquilo inferior o -S(O)2NHR.
ARP070104247A 2006-09-28 2007-09-26 Derivados de quinolina con actividad sobre el receptor 5-ht5a AR062994A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121449 2006-09-28

Publications (1)

Publication Number Publication Date
AR062994A1 true AR062994A1 (es) 2008-12-17

Family

ID=38925599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104247A AR062994A1 (es) 2006-09-28 2007-09-26 Derivados de quinolina con actividad sobre el receptor 5-ht5a

Country Status (18)

Country Link
US (1) US7825253B2 (es)
EP (1) EP2076495B1 (es)
JP (1) JP5111509B2 (es)
KR (1) KR101088451B1 (es)
CN (1) CN101516852B (es)
AR (1) AR062994A1 (es)
AT (1) ATE478050T1 (es)
AU (1) AU2007302061B2 (es)
BR (1) BRPI0717140A2 (es)
CA (1) CA2664031A1 (es)
CL (1) CL2007002768A1 (es)
DE (1) DE602007008597D1 (es)
ES (1) ES2347193T3 (es)
IL (1) IL197301A0 (es)
MX (1) MX2009003170A (es)
PE (1) PE20080898A1 (es)
TW (1) TW200819433A (es)
WO (1) WO2008037626A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669590A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
KR101192952B1 (ko) 2007-09-27 2012-10-18 에프. 호프만-라 로슈 아게 5-ｈｔ5ａ 수용체 길항제로서의 퀴놀린 유도체
JP2011513352A (ja) 2008-03-07 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ（５ａ）受容体アンタゴニストとしての２−アミノキノリン誘導体
WO2009109491A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
EP2254666A1 (en) * 2008-03-12 2010-12-01 F. Hoffmann-La Roche AG 2-aminoquinolines as 5-ht5a receptor antagonists
AR116628A1 (es) 2018-10-18 2021-05-26 Syngenta Crop Protection Ag Compuestos microbiocidas
GB201903942D0 (en) 2019-03-22 2019-05-08 Syngenta Crop Protection Ag Microbiocidal compounds
AU2021232616A1 (en) 2020-03-05 2022-09-22 Syngenta Crop Protection Ag Fungicidal compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
CA2468015A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
JP2005154434A (ja) * 2003-11-05 2005-06-16 Kyowa Hakko Kogyo Co Ltd ２−アミノキナゾリン誘導体

Also Published As

Publication number Publication date
WO2008037626A1 (en) 2008-04-03
ATE478050T1 (de) 2010-09-15
CN101516852A (zh) 2009-08-26
US20080081907A1 (en) 2008-04-03
CN101516852B (zh) 2011-11-16
KR20090042977A (ko) 2009-05-04
CL2007002768A1 (es) 2008-04-18
BRPI0717140A2 (pt) 2013-10-22
JP2010504939A (ja) 2010-02-18
IL197301A0 (en) 2009-12-24
JP5111509B2 (ja) 2013-01-09
TW200819433A (en) 2008-05-01
PE20080898A1 (es) 2008-08-06
AU2007302061B2 (en) 2012-01-19
EP2076495A1 (en) 2009-07-08
DE602007008597D1 (de) 2010-09-30
KR101088451B1 (ko) 2011-12-01
AU2007302061A1 (en) 2008-04-03
MX2009003170A (es) 2009-04-03
ES2347193T3 (es) 2010-10-26
US7825253B2 (en) 2010-11-02
CA2664031A1 (en) 2008-04-03
EP2076495B1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AR062994A1 (es) Derivados de quinolina con actividad sobre el receptor 5-ht5a
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
CR10346A (es) Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3
CR11021A (es) Derivados de quinolina como fungicidas
PE20140968A1 (es) Derivados de benzamida sustituida
ECSP066773A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
EA201100763A1 (ru) Методы получения хинолиновых производных
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
CO6190620A2 (es) Triazoles biciclicos como moduladores de la proteina cinasa
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b
CR10027A (es) Nuevos derivados de pirrol fusionado
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR082004A1 (es) Compuestos de fusion de piridina
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR053790A1 (es) Acidos biariloximetilarencarboxilicos. procesos de obtencion y composiciones farmaceuticas.
AR049401A1 (es) Aza-biciclononanos
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
AR069814A1 (es) Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure